Abgenix
Abgenix is a company.
Active
Updated: ·
About
Abgenix is a company.
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Abgenix.
Abgenix is a company.
Abgenix is a company.
Key people at Abgenix.
Key people at Abgenix.
Abgenix was a biopharmaceutical company focused on discovering, developing, and manufacturing fully human monoclonal antibodies for treating diseases like cancer, inflammation, and infectious conditions.[1][2][3] Its core technology, XenoMouse, enabled production of human antibodies by engineering mice with human antibody genes, addressing unmet needs in therapeutics such as ABX-EGF (later Vectibix/panitumumab) for cancer.[1][2] The company served pharmaceutical partners like Amgen, Bristol-Myers Squibb, and Merck through collaborations, raised $246.64M, and grew to 250-500 employees before being acquired by Amgen in 2006 for full ownership of key assets like panitumumab and to eliminate royalties on denosumab.[2][3][4]
Founded in 1995 (or 1996 per some records) in Fremont, California, Abgenix started with four entrepreneurs—Scott Greer, Raju Kucherlapati, Raymond Withy, and Robert Tepper—who bootstrapped it with $1 million of personal funds.[1][2][3] The idea emerged from advancing monoclonal antibody technology, specifically creating the XenoMouse strain to produce fully human antibodies, reducing immunogenicity issues in therapies.[1] Early traction included partnerships with major biopharma firms, first clinical trials of ABX-EGF in 2001, acquisition of Antigenics in 2003, and FDA approval of Vectibix in 2005 via Amgen collaboration, culminating in Amgen's full acquisition in April 2006.[1][4]
Abgenix rode the late-1990s biotech boom in antibody therapeutics, capitalizing on genomics and genetic engineering to solve immunogenicity challenges in monoclonal antibodies—a market force shifting from murine to fully human therapies.[1][3] Timing was ideal amid rising demand for targeted cancer treatments, with XenoMouse enabling faster, safer drug discovery amid the Human Genome Project's influence.[1][2] It influenced the ecosystem by validating antibody platforms (e.g., panitumumab's approval advanced colorectal cancer care) and through Amgen's 2006 acquisition, consolidating expertise to scale production for millions of patients, boosting oncology biopharma confidence.[4]
Abgenix's legacy endures through Amgen's portfolio: panitumumab (Vectibix) remains a standard in oncology, while denosumab royalties were eliminated, freeing resources for broader innovation.[4] Post-acquisition, its XenoMouse tech integrated into Amgen's operations, contributing to supportive care for over six million cancer patients.[4] Looking ahead, trends like antibody-drug conjugates and next-gen immunotherapies (echoed in successors like Oxford BioTherapeutics) build on Abgenix's foundation, with its Fremont HQ and patents shaping modern biopharma's push for humanized therapies against resistant cancers and pandemics.[2][3] As a pioneer, Abgenix exemplified how bootstrapped biotech can redefine antibody discovery, paving Amgen's path to global leadership.
